Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
about
The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.Quantitative Prediction of Drug-Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?A Pharmacokinetic Modeling Approach to Predict the Contribution of Active Metabolites to Human Efficacious Dose.Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.Use of Human Plasma Samples to Identify Circulating Drug Metabolites that Inhibit Cytochrome P450 Enzymes.
P2860
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
description
2016 nî lūn-bûn
@nan
2016 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մարտին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
name
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
@ast
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
@en
type
label
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
@ast
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
@en
prefLabel
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
@ast
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data.
@en
P2093
P2860
P356
P1476
Mechanistic Modeling to Predict Midazolam Metabolite Exposure from In Vitro Data
@en
P2093
Ernesto Callegari
Hoa Q Nguyen
R Scott Obach
P2860
P304
P356
10.1124/DMD.115.068601
P50
P577
2016-03-08T00:00:00Z